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Diseases of the gallbladder are common and costly.  The 
best epidemiological screening method to accurately deter-
mine point prevalence of gallstone disease is ultrasonogra-
phy.  Many risk factors for cholesterol gallstone formation are 
not modifiable such as ethnic background, increasing age, 
female gender and family history or genetics.  Conversely, the 
modiﬁ  able risks for cholesterol gallstones are obesity, rapid 
weight loss and a sedentary lifestyle.  The rising epidemic of 
obesity and the metabolic syndrome predicts an escalation 
of cholesterol gallstone frequency.  Risk factors for biliary 
sludge include pregnancy, drugs like ceftiaxone, octreotide 
and thiazide diuretics, and total parenteral nutrition or fasting.   
Diseases like cirrhosis, chronic hemolysis and ileal Crohn’s 
disease are risk factors for black pigment stones.  Gallstone 
disease in childhood,  once considered rare,  has become 
increasingly recognized with similar risk factors as those in 
adults, particularly obesity. Gallbladder cancer is uncommon 
in developed countries. In the U.S., it accounts for only ~ 5,000 
cases per year. Elsewhere, high incidence rates occur in 
North and South American Indians.  Other than ethnicity and 
female gender, additional risk factors for gallbladder cancer 
include cholelithiasis, advancing age, chronic inﬂ  ammatory 
conditions affecting the gallbladder, congenital biliary abnor-
malities, and diagnostic confusion over gallbladder polyps.   
(Gut Liver 2012;6:172-187)
Key Words: Gallstones; Cholecystectomy; Gallbladder polyps; 
Gallbladder cancer
INTRODUCTION
Diseases of the gallbladder commonly manifest as gallstones 
and gallbladder cancer. To identify risk factors in a given popu-
lation, epidemiological studies must first define the frequency 
of disease. Studies employing necropsy surveys or healthcare 
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databases carry biases by their implicit nature: being postmor-
tem or requiring biliary symptoms/complications, respectively.
1-3 
Another potential measure of disease burden, the frequency of 
cholecystectomy, is a limited marker for the prevalence of gall-
stones, as the perceived threshold for surgery and patient access 
to care differ greatly.
4 Some epidemiological studies have been 
confounded by inadequate sample size or selection bias. Small 
sample size is open to a beta-II type error: a failure to accurately 
identify a true difference (i.e., a false negative result). Selection 
bias may lead to spurious differences (i.e., a false positive result). 
More reliable epidemiological studies now use transabdominal 
ultrasound to screen robust numbers in defined asymptomatic 
populations. Ultrasonography is an ideal means to quantitate 
the frequency of gallstone disease, being a noninvasive and safe 
imaging technique that accurately can detect the point preva-
lence of gallstones in a defined asymptomatic population. 
GALLSTONE DISEASE
1. Burden of gallstone disease
Gallstones constitute a significant health problem in devel-
oped societies, affecting 10% to 15% of the adult population, 
meaning 20 to 25 million Americans have (or will have) gall-
stones.
2,5-7 The resultant direct and indirect cost of gallbladder 
disease represents a consumption of ~$6.2 billion annually in 
the U.S., constituting a major health burden that has increased 
more than 20% over the last 3 decades.
2,8,9 With an estimated 1.8 
million ambulatory care visits each year, gallstone disease is a 
leading cause for hospital admissions related to gastrointestinal 
problems.
10 These numbers are likely an underestimate because 
laparoscopic cholecystectomy is often performed as a day pro-
cedure and thus not captured by hospital statistics that require 
overnight admission. Although the mortality rate for gallstones 
disease is relatively low at 0.6%, the high burden of disease 
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gallstone-related deaths for 2004 in the U.S. Fortunately, case 
fatality rates have steadily diminished from over 5,000 deaths in 
1950, falling >50% between the years 1979 and 2004. This de-
cline represents the greatest decrease for any digestive disease.
9
Gallstone disease per se also carries inherent risks. Prospective 
population-based surveys have revealed an increased overall 
mortality, particularly from cardiovascular disease and cancer, 
as seen in Americans and Pima Indians with cholelithiasis.
11,12 
Further, as the incidence of gallstone disease escalates, there is 
a concomitant increase in complications like gallstone-related 
pancreatitis.
13
The number of surgical procedures for cholelithiasis has risen 
markedly in developed countries since 1950.
14 The introduc-
tion of laparoscopic cholecystectomy in 1989 further increased 
the cholecystectomy rate.
14-16 From 1990 to 1993, for example, 
there was a 28% escalation in the number of cholecystectomies 
performed.
17 The change in practice emanated from the lapa-
roscopic surgical approach, which represented a less invasive, 
more cosmetically acceptable operation while providing a lower 
surgical risk compared to the then conventional or “open” pro-
cedure. This likely resulted in more surgeries being done in pa-
tients previously thought to be too high a risk, or in those with 
minimal symptoms. Although there is undoubtedly an element 
of overuse, cholecystectomy is now the most common elective 
abdominal surgery performed in the U.S., with over 750,000 
operations being performed annually.
6,16,18 The cholecystectomy 
rate, though increased, fortunately appears to have stabilized in 
the late 1990s and may even be on the decline in the U.S.
19
2. Clinical aspects of gallstone disease
1) Asymptomatic/Silent gallstones 
Gallstones are common. 10% to 20% of Americans will 
develop stones at some time.
20 The majority will not develop 
symptoms: up to 80% will never experience biliary pain or 
complications such as acute cholecystitis, cholangitis, or pan-
creatitis.
21 Hence, most gallstones are clinically “silent,” an in-
cidental finding often uncovered during abdominal ultrasound 
being performed for another reason.
22 People with such asymp-
tomatic cholelithiasis, however, eventually may develop symp-
toms (biliary pain) that require treatment,
23 but this risk is quite 
low averaging 2% to 3% per year,
24 10% by 5 years.
1,23 An even 
lower proportion, 1% to 2% per year, develop major gallstone 
complications.
20,25 Therefore, expectant management is an ap-
propriate choice for silent gallstones in the general population. 
The exception is patients at high risk for experiencing biliary 
complications: 
(1) Large gallstones (>3 cm) or gallbladders crammed with 
stones that carry a higher risk of developing gallbladder cancer, 
perhaps an indication for prophylactic cholecystectomy.
26,27 
(2) Sickle cell disease is associated with the development of 
pigment gallstones, frequently necessitating cholecystectomy. 
Prophylactic cholecystectomy should be considered because 
stone complications is frequently difficult to distinguish from 
the clinical features of a sickle cell crisis or its complications 
such as infarction of the liver or abdominal viscera.
28 When per-
formed early, outside the emergency setting, cholecystectomy 
lessens the surgical risks, but still carries a high mortality rate at 
1% and postoperative complications of >30%.
29
(3) Solid organ transplantation (heart, lung, kidney, pancreas). 
Although stem cell (bone marrow) transplantation carries its 
own problems from cholelithiasis and biliary sludge developing, 
more problematic is the aftermath of solid organ transplantation 
in which gallstones that develop frequently progress to symp-
toms and complications like cholecystitis, principally during the 
first 2 years.
30 Liver transplantation is exempt; the gallbladder 
is removed at the time of hepatectomy. Controversy exists in 
patients with asymptomatic gallstone disease who are undergo-
ing solid organ transplantation: expectant management with 
routine screening ultrasonography vs prophylactic (pre-/post-
transplantation) cholecystectomy. 
(4) Abdominal surgery, performed for other reasons, may 
benefit from a simultaneous cholecystectomy in situations 
where the risk of gallstone formation and complications are 
high. Prophylactic cholecystectomy therefore should be consid-
ered in morbidly obese patients undergoing bariatric surgery.
31
2) Symptomatic gallstone disease
Since most gallstones are asymptomatic, it is essential to 
define exactly which symptoms are caused by gallstones: true 
biliary pain and/or complications, versus nonspecific abdominal 
complaints including dyspepsia.
32-34 Gallstone-associated pain 
seems to follow a certain pattern in most patients.
35,36 Consen-
sus groups have attempted to establish criteria for biliary pain 
relative to defined characteristics (e.g., episodic, steady, severe 
pain located in the upper abdomen and lasting more than 30 
minutes) and some accompanying features (e.g., nocturnal on-
set; nausea and vomiting; radiating through to the back).
11 The 
importance for clarifying what constitutes true biliary pain is 
to better predict relief following cholecystectomy. Currently, 
cholecystectomy does not relieve biliary pain in 10% to 33% 
of people with documented gallstones.
37,38 Confusion with other 
functional gut disorders like irritable bowel syndrome (IBS) and 
dyspepsia will not provide a favorable outcome from cholecys-
tectomy.
39,40 The avoidance of an unnecessary cholecystectomy 
becomes critically germane in an era of escalating rates of sur-
gery.
3) Functional (acalculous) gallbladder disease
Biliary pain seemingly results from increased intraluminal 
pressure as the gallbladder contracts against an obstructed out-
let. In gallstone disease, the obstruction is obvious: a stone in 
the cystic duct. In functional gallbladder disease (also termed; 
acalculous gallbladder disease, gallbladder dyskinesia or biliary 
dyskinesia), the pain mechanism may be obstruction located at 174  Gut and Liver, Vol. 6, No. 2, April 2012
the gallbladder outlet, incoordination between gallbladder con-
traction and sphincter of Oddi relaxation, or visceral hypersen-
sitivity. A clue to its existence is impaired gallbladder emptying, 
reliably quantitated by cholecystokinin-cholescintigraphy.
41,42 
Yet the frequency and management of acalculous gallbladder 
disease remains unclear. Eliminating the apparent problem, the 
gallbladder, via laparoscopic cholecystectomy is fraught with 
challenges, particularly in selecting those who would most 
benefit. Although the exact frequency of biliary dyskinesia is 
unknown, any increase in the employment of cholecystectomy 
for such cases most certainly would impact surgical rates. Thus, 
there is insufficient evidence to support a role for cholecystec-
tomy in functional gallbladder disease at this time.
43 Hence, 
patients with suspected functional biliary pain but whose intact 
gallbladder lacks ultrasonographic evidence of gallstones should 
be carefully evaluated to exclude other causes for their symp-
toms.
3. Risk factors for gallstone formation 
Important risk factors have been identified as being associ-
ated with gallstones (Table 1).
2 Multiple case-control studies, 
comparing those with gallstones versus those without, have 
shown that gallstone formation is multifactorial. Some features, 
such as ethnicity, genetics, advancing age and female gender 
cannot be modified, whereas others (e.g., diet, physical activity, 
rapid weight loss and obesity) are modifiable. 
1) Ethnicity
Geography and particularly ethnicity play an enormous role 
in the prevalence of gallstone disease and also the type of stone 
that forms: cholesterol gallstones predominate in the developed 
countries of the Western world; brown pigment stones in the 
bile ducts are more common in Asia (Table 2, Fig. 1).
44
North American Indians have the highest reported rates of 
cholelithiasis, afflicting 64.1% of women and 29.5% of men.
2,45 
The aboriginal populations of South America also have an 
exceedingly high prevalence of gallstones: 49.4% of native 
Mapuche Indians of Chile women and 12.6% of men harbor 
gallstones.
46 Mexican Americans are also at heightened risk 
when compared to White Americans; however, this risk is di-
rectly related to the degree of Amerindian admixture.
47-50 White 
Americans have an overall prevalence of 16.6% in women and 
8.6% in men.
6,47 Intermediate prevalence rates occur in Asian 
populations
51,52 and Black Americans (13.9% of women; 5.3% 
of men).
6 The lowest frequencies occur in sub-Saharan Black 
Africans (<5%).
53 The majority of gallstones in developed coun-
tries consist predominantly of cholesterol (>85%), whereas the 
remainder constitutes black pigment stones (i.e., composed of 
calcium bilirubinate) (Table 2).
2,7
The situation differs in East Asia where brown pigment stones 
are located in bile ducts, predominately associated with parasitic 
infestation. In developed countries, however, these bile duct 
stones arise in association with the inflammation and infection 
that result from biliary strictures and malignancies. Brown pig-
ment stones consist of some calcium bilirubinate (hence their 
dark color), fatty acid soaps (calcium palmitate and calcium 
stearate, hence their greasy feel), some cholesterol, and muci-
nous glycoproteins (a product of bacterial biofilms). They form 
de novo in the common bile duct (choledocholithiasis) or the 
intrahepatic bile ducts (hepatolithiasis). These primary ductal 
stones result from bacterial infection, biliary parasites (Clonor-
chis sinensis, Opisthorchis species, Fasciola hepatica) and stasis 
from partial biliary obstruction. Brown pigment stones are the 
predominant type in Asia where they can cause Oriental chol-
angiohepatitis: biliary obstruction with recurrent cholangitis, 
dilatation and stricturing of the biliary tree. In hepatolithiasis, 
stones are present in the intrahepatic bile ducts, regardless of 
any coexistent stones residing elsewhere in the biliary system 
(i.e., the extrahepatic ducts or the gallbladder). The brown pig-
ment stones that arise in intrahepatic sites (hepatolithiasis) pos-
sess relatively more cholesterol and less bilirubin than those that 
form in extrahepatic sites, presumably due to a different mecha-
nism for their formation. The frequency of hepatolithiasis, as 
a proportion of all bile duct stones, is as high as 20% in China 
and Taiwan, yet as low at 2% to 3% in Japan, Singapore, and 
Hong Kong.
54 The stone type curiously has recently shifted in 
developing Asian countries from pigment to cholesterol stones. 
The basis for this change may reflect a decreased rate of chronic 
Table 1. Risk Factors for Gallstone Disease
Not modifiable Modifiable
Family history Obesity/metabolic syndrome/diabetes mellitus/dyslipidemia
Genetic predilection Drugs – ceftriaxone, octreotide, thiazide diuretics, female sex hormones
Ethnic background Reduced physical activity
Female sex Rapid weight loss
Age TPN
Diet
Underlying disease: cirrhosis, Crohn’s disease
TPN, total parental nutrition.Stinton LM, et al: Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer  175
biliary infections and consumption of a more Westernized diet.
2
2) Family history & genetics 
Genetic susceptibility is a key factor in gallstone formation.
55 
Familial studies reveal an increased frequency: a nearly 5 times 
elevated risk in the relatives of gallstone patients. These rate 
are even higher in monozygotic twins at 12% and dizygotic 
twins at 6%.
56,57 Yet spouses of affected patients do not have 
any increased risk, thereby eliminating a shared environment as 
the basis - i.e., similar dietary and other common habits among 
family members as the explanation for this apparent associa-
tion.
58 In a Swedish twin study, genetic effects accounted for 
25%, shared environmental influences for 13% and unique en-
vironmental effects for 62% of the phenotypic variance.
59
No mode of simple Mendelian pattern of inheritance can ac-
count for the majority of cases with gallstone disease. In fact, 
stone formation is a complex interaction of genes and environ-
mental factors, particularly diet-gene interactions.
55,60 Several 
genes have been associated with gallstone disease.
61 Identified 
so far have been: the apolipoproteins E (APOE) and B (APOB),
62 
cholesterol ester transporting protein (CETP), cholesterol 7 
α-hydroxylase,
63 cholecystokinin receptor A (CCKAR),
64 the LDL 
receptor (LDLR)
65 and the CETP.
66 Genome-wide association 
analysis has revealed that variants for the hepatic cholesterol 
Table 2. Types of Gallbladder and Biliary Tract Stones: Characteristics and Clinical Associations
Cholesterol gallstones Black pigment stones Brown pigment stones Biliary sludge (microlithiasis)
Composition Cholesterol (50-100%) Calcium bilirubinate polymer  Unconjugated bilirubin, 
calcium soaps of fatty acids, 
cholesterol & mucin
Pigment (calcium-bilirubi-
nate), cholesterol 
microcrystals & mucin
Location Gallbladder
±common duct (~10%)
Gallbladder
±common duct
Bile ducts Gallbladder
Detection Ultrasonography Ultrasonography Cholangiography Abdominal or endoscopic 
ultrasonography; 
microscopy of bile
Clinical associations Metabolic: family history 
(genetic traits), obesity, 
female sex, aging
[excessive cholesterol 
secretion]
Increased or altered bilirubin 
excretion in hemolysis, cir-
rhosis, cystic fibrosis, Crohn’s 
disease, advanced age
[excessive bilirubin excretion]
Infection, inflammation,
infestation [stasis, strictures]
Fasting, TPN, pregnancy-
possible prelude to stone 
formation
TPN, total parental nutrition.
Fig. 1. Worldwide prevalence of gallstones in females based on ultrasonographic surveys varies.
45 Prevalence is inordinately high in American 
Indians and their admixtures, and also Northern Europeans; somewhat lower in European and American whites; intermediate in Asians and black 
Americans, and quite low in black Africans.176  Gut and Liver, Vol. 6, No. 2, April 2012
secretion (ABCG8 19H and ABCB4) represent a susceptibility 
factor for human gallstones.
67,68 Conferring an odds ratios of 2 
to 3 for heterozygous and 7 for homozygous carriers, these vari-
ants account for 11% of the total gallstone risk. Such human 
susceptibility (“gallstone”) genes therefore are not common and 
so embody a rather modest contribution. Cholelithiasis most 
likely is a polygenetic disease entity.
3) Age
The frequency of gallstones increases with age, escalating 
markedly after age 40 to become 4 to 10 times more likely 
in older individuals.
2,69 The stone type also changes with age: 
initially being composed predominantly of cholesterol (corre-
sponding to an increased cholesterol secretion into and satura-
tion of bile) but in late life tending to be black pigment stones. 
Further, symptoms and complications increase with age, leading 
to more frequent cholecystectomies.
70
4) Gender and female sex hormones
The female gender has a most compelling association with 
gallstone disease, especially during the fertile years. Women are 
almost twice as likely as men to form stones; the gap narrows 
following menopause after which men begin to catch up.
2 The 
underlying mechanism is female sex hormones; parity, oral con-
traceptive use and estrogen replacement therapy are established 
risk factors for cholesterol gallstone formation.
71-73 Female sex 
hormones adversely influence hepatic bile secretion and gall-
bladder function. Estrogens increase cholesterol secretion and 
diminish bile salt secretion, while progestins act by reducing 
bile salt secretion and impairing gallbladder emptying leading 
to stasis. A new 4th generation progestin, drospirenone, used in 
some oral contraceptives may further heighten the risk of gall-
stone disease and cholecystectomy; however, the increased risk 
is quite modest and not likely to be clinically meaningful.
74
During pregnancy when female sex hormones are endog-
enously raised, biliary sludge (particulate material that is com-
posed of cholesterol, calcium bilirubinate, and mucin) appears 
in 5% to 30% of women. Resolution frequently transpires dur-
ing the post-partum period: sludge disappears in two-thirds; 
small (<1 cm) gallstones (microlithiasis) vanish in one-third, but 
definitive gallstones become established in ~5%.
75,76 Additional 
risk factors for stone formation during pregnancy include obe-
sity (prior to the pregnancy), reduced high density lipoprotein 
(HDL) cholesterol and the metabolic syndrome.
76,77
5) Obesity
The exploding prevalence of obesity now reaches epidemic 
levels in both developed and developing nations like China.
78,79 
Obesity, particularly abdominal or centripetal obesity, is a 
well-established risk factor for gallstone disease.
2,80-83 At least 
25% of morbidly obese individuals have evidence of gallstone 
disease.
84 Obesity in the late teenage years carries the greatest 
risk, whereas thinness protects against cholelithiasis.
2,85 Females 
with obesity have an even increased risk of stones formation. 
Women with severe obesity (body mass index [BMI] >32 kg/m
2) 
showed an age-adjusted relative risk of 6.0 for the development 
of gallstones compared with nonobese controls; their annual 
incidence of developing gallstones is 2%.
85 Obesity is associated 
with an increased activity of the rate-limiting step in cholesterol 
synthesis, the hepatic enzyme, 3-hydroxyl-3-methyl-glutaryl 
co-enzyme A (HMG-CoA) reductase, leading to increased cho-
lesterol synthesis in the liver and its heightened secretion into 
bile.
80,86,87
6) Dyslipidemia, diabetes mellitus and the metabolic syn-
drome
Cholesterol gallstone disease is a metabolic problem, which 
correlates with lipid abnormalities, diabetes mellitus and adipos-
ity. A low HDL cholesterol
88 and hypertriglyceridemia
89,90 carry 
an increased risk of developing stones. In contrast, there is no 
definite association with hypercholesterolemia.
2,91 High homo-
cysteine levels also may correlate with gallstone disease.
92
The metabolic syndrome is defined by the presence of at least 
3 features out of: abdominal obesity, high blood pressure, high 
fasting glucose, increased triglyceride levels and reduced HDL 
levels.
93,94 Both the metabolic syndrome and diabetes mellitus 
are risk factors for gallstone disease.
95 The metabolic syndrome 
has also been associated with stone complications.
96 Insulin 
resistance predisposes to cholesterol gallstone formation,
97,98 
suggesting altered cholesterol and bile salt metabolism. Hepatic 
insulin resistance may act by enhancing hepatic cholesterol se-
cretion, depressing bile salt synthesis and/or impairing gallblad-
der motility.
99-101
7) Rapid weight loss
Low caloric diets and/or bariatric surgery with rapid weight 
loss are associated with gallstones developing in 30% to 71% of 
such individuals.
102-108 Weight loss that exceeds 1.5 kg/wk fol-
lowing bariatric surgery increases the risk for stone formation; 
these stones are most likely to become apparent during the first 
6 weeks after surgery when weight loss is most profound.
109,110 
Weight loss-associated gallstones are typically asymptomatic; 
only 7% to 16% develop symptoms, best predicted by a postop-
erative weight loss exceeding 25% of the body weight.
84 Even 
less extreme weight fluctuations create a risk for stone forma-
tion,
111 as is a history of dieting.
112
8) Diet and total parental nutrition (TPN)
Other than a high caloric intake that leads to obesity, any 
importance of the dietary content is unclear and difficult to 
analyze.
113-115 Diets specifically high in cholesterol,
116 fatty ac-
ids,
117 carbohydrates
118,119 or legumes
120 seem to increase the 
risk of cholelithiasis. In contrast, unsaturated fats,
121 coffee,
122,123 
fiber,
124,125 ascorbic acid (vitamin C),
126,127 calcium
114 and moder-Stinton LM, et al: Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer  177
ate consumption of alcohol
118,124,128 reduce the risk. Certainly, the 
shift to a more Western diet, high in refined carbohydrates and 
fat (triglycerides) and low in fiber, best explains the profound 
increase in cholesterol gallstones amongst American Indians 
(unmasking their presumed genetic burden) and in European 
countries following World War II. This dietary change also 
might account for the shift from pigment to cholesterol stones 
in Asian countries
2,129,130 Genetic variations, especially in the 
genes that control cholesterol metabolism, might underscore 
why some respond to dietary change by developing cholesterol 
gallstones.
16,60
TPN is a well-known risk factor for developing microlithia-
sis (biliary sludge) and gallstone disease, in addition to acute 
acalculous cholecystitis in critically ill patients.
131-134 In an in-
tensive care setting, biliary sludge appears after 5 to 10 days of 
fasting.
17,49 After 4 weeks of TPN, half of those on TPN develop 
gallbladder sludge on ultrasonography; after 6 weeks all show 
evidence of sludge.
135 Most are asymptomatic. Fortunately, 
sludge resolves within 4 weeks of discontinuing TPN and re-
suming an oral intake, a pattern similar to sludge appearing 
during pregnancy and rapid weight loss and then disappearing 
once the inciting event resolves.
136 A possible explanation for 
this relates to loss of the enteric stimulation of the gallbladder in 
the absence of eating, leading to gallbladder stasis.
134 Addition-
ally, ileal disorders such as Crohn’s disease or ileal resection, in 
which TPN is frequently required, can affect the enterohepatic 
cycling of bile acids and so augment bilirubin absorption and 
subsequent hepatic excretion.
86
9) Lifestyle factors and socioeconomic status
The exact role of socioeconomic status and gallstones is con-
troversial.
2 A previous cross-sectional study of non-Hispanic 
Whites and Mexican Americans, found gallbladder disease 
inversely related to socioeconomic status.
137 Socioeconomic 
status, however, may merely be an indirect marker for other risk 
factors like obesity and chronic medical conditions. The role of 
smoking in cholelithiasis is unclear.
138
Reduced physical activity heightens the risk of gallstone 
disease whereas increased physical activity helps prevent cho-
lelithiasis, independent of its role in weight loss.
122,139 Increased 
endurance exercise (to 30 minutes 5 times a week) may avert 
symptomatic gallstones developing in men.
140
10) Underlying chronic diseases
(1) Liver disease 
Advanced cirrhosis is a well-established risk factor for gall-
stones, with an overall prevalence at 25% to 30%.
141-143 Usually 
the stones consist of the black pigment type in patients with 
cirrhosis.
144 This is likely related to altered pigment secretion, 
abnormal gallbladder motility and/or increased estrogen levels.
2 
Gallstone disease is also associated with chronic hepatitis C viral 
infection and nonalcoholic fatty liver disease;
145-147 other factors 
for this are the metabolic syndrome and obesity.
148
(2) Crohn’s disease
There is a two-three fold increased risk of developing gall-
stones in patients with extensive ileal Crohn’s disease.
77,149 An 
obvious explanation for this is ileal disease or loss leading to 
bile acid malabsorption and depletion, reduced hepatic secretion 
of bile acids and bile that is supersaturated with cholesterol, 
leading to cholesterol stone formation. The cholesterol content 
in bile however can be rather normal or even low in these pa-
tients.
150 Instead, there appears to be an increased frequency of 
pigment stones. Failure of terminal ileal transport in Crohn’s 
disease allows excess bile acids to escape into the colon, where 
these biological detergents solubilize unconjugated bilirubin 
and so facilitate their absorption and return to the liver. The 
liver then secretes excessive pigment that subsequently pre-
cipitates as gallstones.
151 Other explanations include fasting in 
patients with Crohn’s disease, or altered bacterial colonic flora 
that enhance the deconjugation of bilirubin, which can then be 
passively absorbed; the result is an upregulated enterohepatic 
cycling of bile pigment.
152
(3) Cystic fibrosis
Similar to ileal Crohn’s disease, cystic fibrosis is associated 
with bile acid malabsorption due to its binding to undigested 
dietary nutrients. Gallstone prevalence in cystic fibrosis is in-
creased 10% to 30%.
153
(4) Other diseases
In sickle cell disease, chronic hemolysis leads to excessive 
bilirubin excretion with the formation of black pigment stones 
composed of calcium bilirubinate. These tend to be small in size, 
permitting some to travel into the common duct; the resultant 
obstruction is low-grade, not necessarily accompanied by duct 
dilation or cholangitis. Due to potential complications and the 
difficulty in distinguishing biliary-type pain from other com-
plications of sickle cell disease, prophylactic cholecystectomy 
should be considered.
29 
Spinal cord injury is associated with a threefold increase in 
gallstone formation.
154-156 Possible explanations for this include 
gallbladder stasis with sludge formation and intestinal hypomo-
tility that alters bile acid metabolism. 
IBS presents with abdominal pain in addition to other fea-
tures, perhaps fostering cholecystectomy as a more common 
operation in patients with IBS. This may reflect inappropriate 
surgery caused by diagnostic confusion
157 or post-surgical IBS 
symptoms as a consequence of the operation.
158
11) Drugs
(1) Octreotide
Octreotide, a long-acting analogue of somatostatin that 
inhibits cholecystokinin release, results in decreased gallblad-
der motility and stasis.
159 Inhibition of cholecystokinin also 
depresses small intestine motility; the resultant intestinal stasis 
enhances the formation of secondary bile acids like deoxycho-178  Gut and Liver, Vol. 6, No. 2, April 2012
lic acid. Deoxycholic acid adversely influences bile formation 
(increasing cholesterol secretion) and augments the synthesis 
of gallbladder mucin (important for the precipitation of choles-
terol microcrystals from bile and their subsequent growth into 
stones). Greater than 50% of patients receiving octreotide ac-
cordingly will develop cholelithiasis, although the majority are 
asymptomatic.
160,161 
(2) Ceftriaxone
Ceftriaxone, a third generation cephalosporin antibiotic, is 
secreted unmetabolized into bile, achieving high concentra-
tions.
86 This can result in biliary sludge and “pseudolithiasis” in 
those patients, particularly children, receiving ceftriaxone. Most 
remain asymptomatic. Meanwhile, the sludge resolves once the 
medication is discontinued.
162,163 
(3) Thiazide diuretics 
Thiazide treatment may increase biliary cholesterol saturation 
leading to gallstones developing.
164 Some case-controlled reports 
have suggested that thiazide use is associated with a heightened 
risk of acute cholecystitis.
165,166 Others have not found any as-
sociation.
140 Most likely, thiazide use conveys a modest effect. 
In one prospective study concerning women taking thiazide 
diuretics, the relative risk of cholecystectomy rose 36% for past 
users and 57% for current users.
167 
(4) Statins
Drugs that inhibit HMG-CoA reductase seem to prevent cho-
lesterol gallstone disease by diminishing cholesterol synthesis in 
the liver and decreasing its secretion into bile.
168
12) Gallbladder disease in children
Cholelithiasis in the pediatric age group has been considered 
rare, historically thought to be black pigment stones related 
to prematurity and TPN use in infants or chronic hemolysis in 
adolescents. Cholesterol stones, in fact, are becoming increas-
ingly more common in children.
169-171 In unselected pediatric 
populations, the prevalence rates are reported between 0.1% to 
1.0%.
170,172 One explanation for this increase is greater access to 
and use of abdominal ultrasonography in children.
173 A more 
prominent factor now is obesity, accounting for some 8% to 
33% of gallstones observed in children.
174,175 In obese children 
and adolescents, the prevalence may be as high as 2.0%.
171 
Other risk factors for gallstone disease in childhood include: 
female gender, pregnancy and oral contraceptive use; being of 
Mexican-American origin; drug exposure to cephalosporins, 
ceftriaxone or diuretics; a history of cardiac surgery or bowel 
resection, and having cystic fibrosis.
149,172,173,176 In fact, the risk 
factors for pediatric gallbladder disease now more closely re-
semble those in adults.
40% to 51% of children with gallstones are asymptomat-
ic.
173,177 Those with no symptoms have a lower rate of complica-
tions, while gallstones may resolve in 17%. Therefore conserva-
tive management is recommended in these children. Pediatric 
patients with symptomatic cholelithiasis are at risk for compli-
cations (18% to 28%); the most common presentation is right 
upper quadrant abdominal pain.
173,178 Complications include 
acute cholecystitis, choledocholithiasis and pancreatitis. 
Laparoscopic cholecystectomy is safe and can be quite effec-
tive in children. Cholecystectomy for children with symptomatic 
gallstones therefore is the standard of care. Surgery is also being 
used more frequently for functional gallbladder disease (biliary 
dyskinesia), an entity that bears scrutiny given the absence of 
clear diagnostic criteria or effective management schemes.
169
GALLBLADDER CANCER
Gallbladder cancer is a notoriously rare though lethal malig-
nancy with marked ethnic and geographical variations. The pre-
senting symptoms are typically vague so that its diagnosis com-
monly occurs at an advanced stage. This late diagnosis plus the 
anatomic feature that the gallbladder lacks a serosa culminates 
in a rather dismal prognosis.
179-181 The overall mean survival rate 
for patients with advanced gallbladder cancer is 6 months, with 
a 5-year survival rate of 5%.
182 Early gallbladder cancer (confined 
to the mucosa), though infrequent, offers the potential for a cure 
though cholecystectomy. Most (>80%) gallbladder cancers are 
adenocarcinomas that originate from the fundus (60%), body 
(30%), or neck (10%). The basis likely is genetic susceptibility, 
perhaps elicited by chronic gallbladder inflammation, often a 
product of cholelithiasis.
181,183,184 One reasonable hypothesis fo-
cuses on chronic irritation of the mucosa (e.g., from the physical 
presence of the stones and/or superimposed chronic infection 
such as from Salmonella typhi) leading to dysplasia (perhaps 
abetted by mutagenic secondary bile acids) and terminating in 
malignant change. 
The risk factors for developing gallbladder cancer therefore 
include ethnicity, genetic susceptibility, lifestyle factors and 
infections. Elucidating such risk factors (Table 3) not only pro-
vides insight into its pathogenesis accounting for its geographic 
and ethnic variances (Fig. 2), but more importantly should yield 
strategies to prevent and treat this unusual malignancy.
185 
1. Ethnicity, gender, and age
Gallbladder cancer is rare in developed countries. In the U.S., 
it only accounts for 0.5% of all gastrointestinal malignan-
cies, accounting for less than 5,000 cases per year (1 to 2.5 per 
100,000).
183 Worldwide, gallbladder cancer has a low occurrence 
<2 per 100,000, but has a wide variance (Fig. 2). High annual 
incidence rates occur in North and South American Indians, 
generating an inordinate mortality, particularly amongst wom-
en: 15.5 per 100,000 in women (vs 7.5/100,000 in men) from 
La Paz, Bolivia, and 11.3 per 100,000 in women (vs 4/100,000 
in men) from New Mexico. Hence, carcinoma of the gallbladder 
is the leading cause of cancer death in Chilean women, exceed-
ing even breast, lung and cervical cancers.
186,187 Other high-risk 
regions are scattered though Eastern Europe (14/100,000 in Po-Stinton LM, et al: Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer  179
land), northern India (as high as 21.5/100,000 for women from 
Delhi) and south Pakistan (11.3/100,000).
185 Intermediate inci-
dences (3.7 to 9.1 per 100,000) occur elsewhere in South Ameri-
cans of Indian descent, and in Israel (5/100,000) and Japan 
(7/100,000).
184 The frequency is increasing in Shanghai, China 
and now accounts for the most frequent gastrointestinal malig-
nancy and is a substantial cause of mortality.
188 Although the 
majority of the world has decreasing mortality trends in gall-
bladder cancer, Iceland, Costa Rica, and Korea have an increase 
in mortality for men.
189 There appears to be a modest decline in 
prevalence over the past two decades (National Cancer Institute. 
Surveillance, Epidemiology and End Results (SEER) Program 
[http://seer.cancer.gov/]).
Gender differences exist with geographic variances, generally 
being unfavorable for women. In those locals with the highest 
incidence, women have frequency rates greater than men. With 
age, gallbladder cancer increases.
2. Gallstones
A history of gallstones appears to carry the highest risk for 
gallbladder cancer, with a relative risk of 4.9.
185 Most (69% to 
100%) but not all people with gallbladder cancer have cho-
lelithiasis. Further, these 2 entities frequently co-exist in the 
same populations, suggesting that stones may function as a 
co-factor for this carcinoma.
190 American Indians, who have a 
quite high prevalence of cholesterol gallstone disease, also have 
a high incidence of carcinoma of the gallbladder; yet in other 
settings, there is a low incidence of gallbladder cancer despite 
an overall high frequency of cholelithiasis. Increasing stone 
size (>3 cm),
191,192 number, volume, and weight, all are associ-
ated with an increased risk of cancer.
190 Less important is the 
duration of cholelithiasis.
193 Cholesterol stones seem to be more 
common than pigment stones in gallbladder cancer patients.
194 
Further attesting to gallstones being a risk factor for gallbladder 
carcinoma, the incidence of this cancer rises when the chole-
cystectomy rate declines.
184,195 Nevertheless, consensus does not 
generally favor prophylactic cholecystectomy for asymptomatic 
stones
196,197 as cholelithiasis is too common and gallbladder can-
Table 3. Risk Factors for Gallbladder Cancer
Risk factor Relative risk Reference
Gallstones 3.01-23.8 218-222
Size of gallstones
   2.0-2.9 cm
   >3.0 cm   
2.4
9.2-10.1
191,223
Duration of gallstones
   5-19 yr
   >20 yr
4.9
6.2
193
BMI
   30.0-34.9
Men            Women
1.8                 2.1
215
Infections
   Chronic typhoid &
     paratyphoid carriers
   Helicobacter bilis
12.7-167
 2.6-6.5
224,225
206,226
Fig. 2. Incidence of gallbladder cancer worldwide (From National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. 
Available from http://seer.cancer.gov/). Carcinoma of the gallbladder is more common in certain ethnic groups: native American Indians, white 
Hispanics from North and South America, and those from northern India and Eastern Europe.
198 Elsewhere in the world, the incidence is low at 
<2/100,000.180  Gut and Liver, Vol. 6, No. 2, April 2012
cer too rare. Potential exceptions include large stones greater 
than 3 cm, which have a risk of 4% over 20 years,
27,198 and el-
derly American Indian females with gallstones.
199 
3. Chronic inﬂ  ammation
Chronic inflammation from any cause may lead to calcium 
being deposited in the gallbladder wall, termed the “porcelain 
gallbladder” because of its bluish color and fragile, brittle con-
sistency.
200 This entity is rare, being identified pathologically 
in less than 1% of gallbladder specimens. The calcium depos-
its can be detected on diagnostic imaging - plain abdominal 
radiographs, ultrasounds or computed tomography images. 
Controversy exists whether or not the porcelain gallbladder is 
truly associated with an increased risk of cancer. Some stud-
ies indicate that 25% (range, 12% to 61%) are associated with 
gallbladder cancer,
199,201 whereas more recent reports negate any 
such association.
202 Only gallbladders with partial calcification, 
stippled or multiple punctate calcifications in the glandular 
spaces of the mucosa, are premalignant and therefore should be 
removed prophylactically. Those with a broad continuous band 
of calcification in the muscularis appear not to be harbingers of 
gallbladder cancer.
Chronic bacterial infections also cause irritation and inflam-
mation in the gallbladder. S. typhi carriers have an 8 to 12-fold 
increased risk with 6% developing gallbladder cancer.
203-205 In 
contrast to typhoid carriers, however, a past history of typhoid 
fever is not associated with the development of gallbladder can-
cer.
206 Helicobacter pilis is also implicated in gallbladder cancer 
with an odds ratio of 6.5 in Japanese patients and 5.86 in Thai 
patients.
206
Primary sclerosing cholangitis (PSC) is typically associated 
with an increased risk of cholangiocarcinoma. As dysplasia oc-
curs in 37% and adenocarcinoma in 14% of gallbladders from 
patients with PSC, their general predilection for biliary carci-
noma as cholangiocarcinoma may place these individuals at 
heightened risk for developing gallbladder cancer.
207
4. Congenital biliary abnormalities
An anomalous pancreaticobiliary junction is a rare congenital 
anomaly of the biliary tract in which the pancreatic and biliary 
ducts join outside the duodenal wall, forming an abnormally 
long channel that lies beyond the sphincter of Oddi.
208 Such an 
anomaly defeats sphincter of Oddi gatekeeper function, poten-
tially allowing pancreatic secretions to regurgitate into the bili-
ary system and gallbladder, and so leading to malignant chang-
es in the mucosa.
209 The anomalous pancreaticobiliary junction 
is more prevalent in Asian (particularly Japanese) populations 
and carries an increased risk of gallbladder cancer at 3% to 
18%.
183,210 Hence, prophylactic cholecystectomy is recommended 
due to the high frequency of gallbladder carcinoma. 
5. Genetic factors 
There are undoubtedly genetic and environmental factors that 
coincide to become expressed as gallbladder cancer. A family 
history of gallbladder cancer is clearly a risk factor.
211,212 The 
only responsible gene so far identified seems to be that for apo-
lipoprotein B function (the APOB gene), which influences cho-
lesterol handling yet is not associated with gallstones. In fact, 
the link between cholesterol gallstones and gallbladder cancer 
may relate to an interdependent disposal pathway that increases 
the export of both cholesterol and environmental toxins into 
bile. As gallbladder cancer is more common in women, such 
mutagenic toxins secreted reside longer in the gallbladder due 
to stasis from impaired contractility associated with the female 
hormone, progesterone. This protracted exposure allows envi-
ronmental carcinogens to then cause malignant transformation, 
helping to reconcile the schism of seed versus soil and incor-
porate the predilection to the development of gallstones (also 
requiring some gallbladder stasis) and gallbladder cancer.
213
6. Gallbladder polyps
Polypoidal masses of the gallbladder affect 5% of adults and 
may be confused with gallbladder cancer.
214 Over two-thirds 
of polyps are composed of cholesterol esters; the other lesions 
are adenomas, leiomyomas or inflammatory polyps. Although 
occasionally associated with biliary colic, the vast majority of 
gallbladder polyps are asymptomatic, being found incidentally 
when abdominal imaging is performed for other purposes. 
Features that predict malignancy are: large polyps (>10 mm), a 
solitary or sessile mass, associated gallstones, patient age over 
50 and most importantly, rapid polyp growth. Prophylactic cho-
lecystectomy is warranted in patients with polyps that possess 
such malignant-appearing features. 
7. Other lifestyle factors
The association of gallstones with gallbladder cancer likely 
explains why some of the traditional risk factors for gallstones 
are also risk factors for gallbladder cancer including obesity, 
female gender, and multiparity. In over 84,000 men and 97,000 
women included in The Cancer Prevention Study II Nutrition 
Cohort, the relative risk of gallbladder cancer was 1.8 (95% 
confidence interval [CI], 1.1 to 2.9) in obese men with a BMI 
of 30.0 to 34.9 compared to men with a normal BMI (18.5 to 
24.9). Obese women (BMI, 30.0 to 34.9) had a relative risk of 2.1 
(95% CI, 1.6 to 2.9) compared to women with a normal BMI.
215 
Overall, obesity has a relative risk of 1.66 (95% CI, 1.47 to 1.88) 
for gallbladder cancer.
216 Other lifestyle risks involve cigarette 
smoking, and alcohol consumption (in men only).
217 
CONCLUSION
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(i.e., prevalence) has advanced with the use of ultrasonographic 
surveys as opposed to previous studies based on clinical or nec-
ropsy evidence.
2,3 These population surveys have better defined 
important risk factors, both unchangeable and modifiable. The 
implications of changing environmental risk factors predict 
an increase in the numbers of individuals with gallstones. An 
aging population plus the rising epidemic of obesity and the 
metabolic syndrome are certain to aggravate the frequency and 
complications of gallstone disease. Identifying risk factors that 
can be altered (i.e., extreme obesity, rapid weight loss, sedentary 
lifestyle, and key dietary factors) should provide an opportunity 
to prevent cholelithiasis. Several risk factors for gallstones are 
also implicated in the pathogenesis of gallbladder cancer. Al-
though the frequency of gallbladder cancer is relatively low in 
the U.S., if the incidence of gallstones rises, gallbladder cancer 
most likely will also increase.  
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